systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-344Research ArticleКАРДИОЛОГИЯCARDIOLOGYДифференцированный подход к первичной профилактике‌‌ сердечно-сосудистых заболеванийA differentiated approach to the primary prevention of cardiovascular diseaseНапалковД. А.NapalkovD. A.dminap@mail.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииRussian Federation201423122022112912Copyright © Напалков Д.А., 20222022Напалков Д.А.Napalkov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/344

В данном обзоре литературы приводится современный анализ к медикаментозным подходам в рамках первичной профилактики сердечно-сосудистых заболеваний. Обсуждается целесообразность применения с этой целью антиагрегантов и статинов, а также новые данные о возможностях профилактики инсульта и инфаркта при включении в схемы антигипертензивной терапии антагониста кальция амлодипина.

The review of literature shows the modern analysis of medical approaches for cardiovascular disease primary prevention. We have been discussing the necessity of antiaggregant and statin therapy in such cases and also studding new results of involving antihypertensivetherapy (calcium antagonist - amlodipine) to prevent stroke and heart attack.

профилактика сердечно-сосудистых заболеванийантиагрегантная терапиягиполипидемическая терапияантигипертензивная терапияамлодипинprevention of cardiovascular diseaseantiaggregant therapycholesterol-lowering treatmentantihypertensive therapyamlodipineReferencesEuropean Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012; 33: 1635-701.European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012; 33: 1635-701.Berger J.S, Lala A, Krantz M.J et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta - analysis of randomized trials. Am Heart J 2011; 162: 115-24 e2.Berger J.S, Lala A, Krantz M.J et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta - analysis of randomized trials. Am Heart J 2011; 162: 115-24 e2.Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-10.Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 405-10.Shaink A. The Effectiveness of statins for primary prevention: a rapid review. 2013; p. 1-23.Shaink A. The Effectiveness of statins for primary prevention: a rapid review. 2013; p. 1-23.Mills E.J, Rachlis B, Wu P et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta - analysis involving more than 65 000 patients. J Am Coll Cardiol 2008; 52 (22):1769-81.Mills E.J, Rachlis B, Wu P et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta - analysis involving more than 65 000 patients. J Am Coll Cardiol 2008; 52 (22):1769-81.Brugts J, Yetgin T, Hoeks S et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta - analysis of randomised controlled trials. BMJ 2009; 7711: 36.Brugts J, Yetgin T, Hoeks S et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta - analysis of randomised controlled trials. BMJ 2009; 7711: 36.Taylor F, Ward K, Moore T.H et al. Statins for the primary prevention of cardiovascular disease. Cochrane database of systematic reviews 2011; CD004816.Taylor F, Ward K, Moore T.H et al. Statins for the primary prevention of cardiovascular disease. Cochrane database of systematic reviews 2011; CD004816.Fretheim A, Odgaard-Jensen J, Brors O et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta - analysis. BMC Medicine 2012; 10: 33.Fretheim A, Odgaard-Jensen J, Brors O et al. Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta - analysis. BMC Medicine 2012; 10: 33.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high - risk hypertensive patients randomized to angiotensin - converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.Dahlöf B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Dahlöf B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.Nissen S.E, Tuzcu E.M, Libby P et al for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial, JAMA 2004; 292: 2217-26.Nissen S.E, Tuzcu E.M, Libby P et al for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial, JAMA 2004; 292: 2217-26.Wang J.G, Li Y, Franklin S.S, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: aquantitative overview. Hypertension 2007; 50: 181-8.Wang J.G, Li Y, Franklin S.S, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: aquantitative overview. Hypertension 2007; 50: 181-8.

The authors declare that there are no conflicts of interest present.